Search results
Results From The WOW.Com Content Network
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. The drug was provided by the company in response to a "compassionate use" (temporary authorization for use) request from the president's physicians.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Regeneron had earlier developed a monoclonal antibody therapy against COVID, which was authorized by the U.S. Food and Drug Administration in November 2020, but its use was limited early last year ...
George D. Yancopoulos (born 1959) is a Greek - American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals. [1] Yancopoulos is the holder of more than 100 patents. [2] He is a principal inventor and developer of Regeneron's ten FDA -approved or -authorized treatments, as well as of ...
According to data released by Regeneron, the phase 3 double-blind, placebo-controlled trial of the experimental drug suggests it could be effective in preventing symptomatic COVID-19 infections.
Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's ...
Regeneron used its VelociGene, VelocImmune and VelociMab antibody discovery and production technologies and coordinated with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). The therapy was developed in six months and a Phase 1 trial in healthy humans was completed in 2015. PALM trial
Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc ...